---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-008700"
form_type: "8-K"
ticker: "IONS"
cik: "0000874015"
company_name: "IONIS PHARMACEUTICALS INC"
filed_at: "2024-02-21T23:59:59+00:00"
generated_at: "2026-06-05T22:32:05.732706+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Ionis Q4 revenue $325M, up 114%; WAINUA approved; 2024 guidance: revenue >$575M

## Summary
- Q4 total revenue $325M (up 114% YoY); full year revenue $788M (up 34%); Q4 operating loss narrowed to $6M from $208M.
- WAINUA (eplontersen) FDA-approved for ATTRv-PN; U.S. launch underway; $50M milestone from AstraZeneca.
- Positive Phase 3 data for olezarsen (FCS) and donidalorsen (HAE); preparing regulatory submissions.
- 2024 guidance: revenue >$575M, non-GAAP operating loss <$475M, cash ~$1.7B.
- SPINRAZA royalties $240M in 2023; QALSODY royalties included; pipeline milestones with bepirovirsen, ION582.

## SEC filing metadata
- accession: 0001140361-24-008700
- form_type: 8-K
- ticker: IONS
- cik: 0000874015
- company_name: IONIS PHARMACEUTICALS INC
- filed_at: 2024-02-21T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/874015/000114036124008700/0001140361-24-008700-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/874015/000114036124008700/ef20022046_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-008700
- JSON: https://secwatch.observer/filing/0001140361-24-008700.json
- Plain text: https://secwatch.observer/filing/0001140361-24-008700.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.